Journal Article

Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective

Al‐Kuraishy, Hayder M., Alexiou, Athanasios, Khalifa, Asmaa A., Alnaaim, Saud A., Ali, Naif H., Al‐Gareeb, Ali I., Papadakis, Marios, Batiha, Gaber El‐Saber, Saad, Hebatallah M.

2024

Overview

Alzheimer's disease (AD) is a heterogeneous neurodegenerative disease with multifaceted neuropathological disorders. AD is characterized by intracellular accumulation of phosphorylated tau proteins and extracellular deposition of amyloid beta (Aβ). Various protease enzymes, including neprilysin (NEP), are concerned with the degradation and clearance of Aβ. Indeed, a defective neuronal clearance pathway due to the dysfunction of degradation enzymes might be a possible mechanism for the accumulation of Aβ and subsequent progression of AD neuropathology. NEP is one of the most imperative metalloproteinase enzymes involved in the clearance of Aβ. This review aimed to highlight the possible role of NEP inhibitors in AD. The combination of sacubitril and valsartan which is called angiotensin receptor blocker and NEP inhibitor (ARNI) may produce beneficial and deleterious effects on AD neuropathology. NEP inhibitors might increase the risk of AD by the inhibition of Aβ clearance, and increase brain bradykinin (BK) and natriuretic peptides (NPs), which augment the pathogenesis of AD. These verdicts come from animal model studies, though they may not be applied to humans. However, clinical studies revealed promising safety findings regarding the use of ARNI. Moreover, NEP inhibition increases various neuroprotective peptides involved in inflammation, glucose homeostasis and nerve conduction. Also, NEP inhibitors may inhibit dipeptidyl peptidase 4 (DPP4) expression, ameliorating insulin and glucagon‐like peptide 1 (GLP‐1) levels. These findings proposed that NEP inhibitors may have a protective effect against AD development by increasing GLP‐1, neuropeptide Y (NPY) and substance P, and deleterious effects by increasing brain BK. Preclinical and clinical studies are recommended in this regard.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc
• Subject: Alzheimer Disease - drug therapy / Alzheimer Disease - metabolism / Alzheimer's disease / Amyloid beta-Peptides - metabolism / Angiotensin / Animal models / Animals / Bradykinin / Brain / Brain natriuretic peptide / Dementia / Enzymes / Glucagon / Glucagon-Like Peptide 1 / Glycoproteins / Homeostasis / Humans / Lipoproteins / Memory / Metabolism / Metalloproteinase / Neprilysin / Neprilysin - metabolism / neprilysin inhibitors / Nerve conduction / Neurodegenerative Diseases / Neurons / Neuropathology / Neuropeptide Y / Neuroprotection / Oxidative stress / Pathogenesis / Peptides / Proteins / Review / Reviews / Substance P / Tau protein / Transgenic animals / β-Amyloid